Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 2940-2950

  Ang, K Kian ^a   Zhang, Qiang ^b   Rosenthal, David I ^a   Nguyen Tan, Phuc Felix ^m   Sherman, Eric J ^d   Weber, Randal S ^a   Galvin, James M ^c   Bonner, James A ^e   Harris, Jonathan ^b   El Naggar, Adel K ^a   Gillison, Maura L ^f   Jordan, Richard C ^g   Konski, Andre A ^h   Thorstad, Wade L ⁱ   Trotti, Andy ^j   Beitler, Jonathan J ^k   Garden, Adam S ^a   Spanos, William J ^l   Yom, Sue S ^g   Axelrod, Rita S ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b Radiation Therapy Oncology Group Statistical Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k EMORY CLINIC   (United States)

^l University of Louisville School of Medicine   (United States)

^m UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEMOGLOBIN; PROTEIN P16; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER LOCALIZATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISTANT METASTASIS; DRUG INDUCED HEADACHE; DYSGEUSIA; DYSPHAGIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK CARCINOMA; HEADACHE; HEARING DISORDER; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; LARYNGITIS; LARYNX EDEMA; LARYNX SQUAMOUS CELL CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NECK PAIN; NEURALGIA; NEUTROPHIL COUNT; OROPHARYNX CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RASH; SALIVARY GLAND DISEASE; SENSORY NEUROPATHY; SKIN FIBROSIS; SKIN MANIFESTATION; SMOKING; SORE THROAT; THROMBOCYTE COUNT; TINNITUS; TRISMUS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CHEMORADIOTHERAPY; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM STAGING; PATIENT SELECTION; RADIATION-SENSITIZING AGENTS; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

EID: 84907200175     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.5633     Document Type: Article

References (33)

1. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomized trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
2. Machtay M, Moughan J, Trotti A, et al: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 26:3582-3589, 2008
3. Rubin Grandis J, Melhem MF, Barnes EL, et al: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284-1292, 1996
4. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
5. Psyrri A, Yu Z, Weinberger PM, et al: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11: 5856-5862, 2005
6. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
7. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
8. Saleh MN, Raisch KP, Stackhouse MA, et al: Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14:451-463, 1999
9. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
10. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006
11. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005
12. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
13. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078, 2006
14. Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365-375, 1974
15. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
16. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003
17. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
18. Begum S, Gillison ML, Ansari-Lari MA, et al: Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469-6475, 2003
19. Chung CH, Zhang Q, Hammond EM, et al: Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 81:331-338, 2011
20. Michiels S, Le Maître A, Buyse M, et al: Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol 10:341-350, 2009
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Kalbfleish J, Prentice R: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
24. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
25. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-229, 1972
26. Van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, et al: Fully conditional specification in multivariate imputation. J Stat Comput Sim 76:1049-1064, 2006
27. Rubin DB (ed): Multiple Imputation for Nonresponse in Surveys. New York, NY, John Wiley & Sons, 1987
28. Resseguier N, Giorgi R, Paoletti X: Sensitivity analysis when data are missing not-at-random. Epidemiology 22:282-283, 2011
29. Amorino GP, Freeman ML, Carbone DP, et al: Radiopotentiation by the oral platinum agent, JM216: Role of repair inhibition. Int J Radiat Oncol Biol Phys 44:399-405, 1999
30. Dittmann K, Mayer C, Fehrenbacher B, et al: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNAdependent protein kinase. J Biol Chem 280:31182-31189, 2005
31. Nakata E, Hunter N, Mason K, et al: C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163-1173, 2004
32. Budach W, Bölke E, Homey B: Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514-515, 2007
33. Ang KK, Sturgis EM: Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22:128-142, 2012